Abstract / Summary
The rapid adoption of glucagon-like peptide-1 receptor agonists and related incretin-based therapies has transformed the treatment of obesity and is beginning to reshape adjacent consumer-health and aesthetic markets. Semaglutide, tirzepatide and next-generation agents can produce degrees of weight reduction that were previously uncommon outside metabolic surgery. That therapeutic success can be accompanied by a second, increasingly visible set of aesthetic and integumentary needs: facial soft-tissue deflation, accentuation of pre-existing laxity and folds, changes in body contour, and hair shedding. These phenomena should not be reduced to the popular but scientifically imprecise label ‘Ozempic face’. In many patients, the dominant drivers are likely to include the magnitude and velocity of weight loss, loss of subcutaneous support, age- dependent limits in tissue recoil, changes in body composition, lower total food intake and pre-existing photoageing. At the same time, emerging mechanistic literature suggests that GLP-1 signalling in skin is complex and may include potentially favourable anti-inflammatory and regenerative effects. The result is not a simple toxicity narrative but a new problem of tissue adaptation during metabolic transformation. This review proposes an independent, evidence-led category: a GLP-1-era dermocosmetic adaptation platform integrating topical facial and body care, scalp and hair care, selected nutricosmetic support, professional aesthetic pathways and prospective clinical validation. The commercial opportunity is potentially significant because it is attached not to one pharmaceutical brand, but to the structural expansion of pharmacological obesity management. Its long-term credibility, however, will depend on disciplined claims, objective endpoints and a clear understanding of what cosmetics can — and cannot — achieve.